Table 2.
Results of overall and subgroup analyses for PAI‐1 rs1799889 A/G polymorphism and VTE
| Dominant comparison (AA vs AG + GG) | Recessive comparison (GG vs AA + AG) | Over‐dominant comparison (AG vs AA + GG) | Allele comparison (A vs G) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Population | Sample size | P value | OR (95%CI) | I 2 statistic | P value | OR (95%CI) | I 2 statistic | P value | OR (95%CI) | I 2 statistic | P value | OR (95%CI) | I 2 statistic |
| Overall | 5731/9075 | 0.30 | 1.10 (0.92‐1.32) | 78% | 0.11 | 0.87 (0.73‐1.03) | 65% | 0.57 | 1.04 (0.92‐1.17) | 55% | 0.21 | 1.04 (0.98‐1.10) | 55% |
| Caucasian | 4460/6609 | 0.0002 | 1.20 (1.09–1.32) | 49% | 0.003 | 0.84 (0.76‐0.94) | 35% | 0.73 | 1.02 (0.93‐1.11) | 21% | 0.01 | 1.08 (1.02‐1.15) | 31% |
| East Asian | 347/356 | 0.004 | 1.60 (1.17–2.19) | 34% | 0.06 | 0.71 (0.50‐1.02) | 21% | 0.28 | 0.83 (0.60‐1.16) | 38% | 0.0004 | 1.53 (1.21–1.93) | 49% |
| West Asian | 483/963 | 0.66 | 0.75 (0.20‐2.80) | 96% | 0.54 | 1.36 (0.51‐3.65) | 91% | 0.80 | 1.12 (0.47‐2.66) | 92% | 0.56 | 0.75 (0.28‐1.99) | 97% |
| DVT | 1778/1645 | 0.06 | 1.16 (0.99‐1.36) | 36% | 0.05 | 0.73 (0.53–0.99) | 55% | 0.84 | 1.02 (0.88‐1.17) | 46% | 0.02 | 1.13 (1.02–1.25) | 47% |
| PE | 254/682 | 0.47 | 1.14 (0.80‐1.61) | 0% | 0.44 | 0.75 (0.36‐1.57) | 65% | 0.41 | 0.88 (0.64‐1.20) | 0% | 0.57 | 1.11 (0.77‐1.60) | 55% |
| Factor V Leiden | 993/1870 | 0.01 | 1.29 (1.06‐1.57) | 5% | 0.06 | 0.68 (0.46‐1.02) | 65% | 0.92 | 0.99 (0.83‐1.19) | 0% | 0.03 | 1.24 (1.02‐1.52) | 60% |
| Cancer | 264/297 | 0.91 | 1.03 (0.57‐1.87) | 57% | 0.46 | 0.81 (0.45‐1.43) | 0% | 0.91 | 0.98 (0.70‐1.38) | 31% | 0.46 | 1.10 (0.85‐1.42) | 50% |
| Surgery | 91/121 | 0.41 | 1.28 (0.71‐2.32) | 0% | 0.41 | 0.73 (0.35‐1.54) | 0% | 1.00 | 1.00 (0.52‐1.91) | 0% | 0.72 | 1.08 (0.71‐1.64) | 0% |
Note: The values in bold represent there is statistically significant differences between cases and controls.
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; NA, not available; OR, odds ratio; PAI‐1, plasminogen activator inhibitor‐1; PE, pulmonary embolism; VTE, venous thromboembolism.